美洛昔康联合硫酸氨基葡萄糖治疗骨关节炎的临床研究  

Clinical trial of meloxicam combined with glucosamine sulfate in the treatment of patients with osteoarthritis

作　　者：韩宏德 蒋家正[1] 张恒林[1] 桑龙[1] 韩贵宾 HAN Hong - de;JIANG Jia - zheng;ZHANG Heng- lin;SANG Long;HAN Gui - bin(Department of Orthopedics, The First People＇s Hospital of Danzhou, Dartzhou 571700, Hainan Province, China)

机构地区：[1]儋州市第一人民医院骨科,海南儋州571700

出　　处：《中国临床药理学杂志》2018年第10期1151-1154,共4页The Chinese Journal of Clinical Pharmacology

基　　金：海南省卫生厅基金资助项目(琼卫-2013资助-036号)

摘　　要：目的观察美洛昔康联合硫酸氨基葡萄糖治疗骨关节炎的临床研究。方法将于我院治疗的骨关节炎患者90例随机分为试验组和对照组,每组45例。对照组给予美洛昔康片7.5 mg,每天2次,口服;试验组在对照组的基础上,给予硫酸氨基葡萄糖胶囊0.5 g,每天3次,口服。2组患者均治疗6周。治疗前后对所有患者临床症状、体征、膝关节运动功能及疼痛指标进行评价;收集血液标本和关节液标本,用酶联免疫吸附(ELISA)法检测基质金属蛋白酶-3(MMP-3)、基质金属蛋白酶^(-1)3(MMP^(-1)3)、前列腺素E_2(PGE_2)水平,同时比较2组患者的临床疗效,并记录药物不良反应发生情况。结果治疗后,试验组与对照组Lequesne指数分别为5.78±3.04和8.24±3.62,Lysholm评分分别为(85.82±10.01)和(72.46±13.58)分,VAS评分分别为(2.45±1.08)和(3.86±1.17)分,血清MMP-3分别为(114.69±13.54)和(130.52±16.48)ng·L^(-1),血清MMP^(-1)3分别为(141.06±21.55)和(179.82±24.37)ng·L^(-1),血清PGE_2分别为(69.82±18.67)和(91.30±20.09)ng·L^(-1);关节液MMP-3分别为(17.89±5.12)和(23.10±5.46)ng·L^(-1),关节液MMP^(-1)3分别为(27.35±6.52)和(38.47±6.85)ng·L^(-1),关节液PGE2分别为(82.16±22.64)和(118.02±23.41)ng·L^(-1),差异均有统计学意义(均P<0.05)。对照组改善率为73.33%(33例/45例),试验组为91.11%(41例/45例),差异有统计学意义(P<0.05)。2组治疗期间无药物不良反应发生。结论美洛昔康联合硫酸氨基葡萄糖治疗骨关节炎的疗效确切,有利于改善临床症状,降低血清MMP-3、MMP^(-1)3、PGE_2含量,安全性高。Objective To investigate the clinical efficacy of meloxicam combined with glucosamine sulfate in the treatment of patients with osteoarthritis. Methods Ninety cases of knee osteoarthritis were randomly divided into control group and treatment group,each group 45 cases. Control group was given meloxicam tablets 7. 5 mg,bid,oral. On the basis of control group,treatment group was treated with glucosamine sulfate capsules 0. 5 g,tid,oral. All the patients were treated for 6 weeks. The clinical symptoms,signs,knee joint motor function and pain indexes of all patients were evaluated before and after treatment. The blood samples and joint fluid specimens were collected,to determine the matrix metalloproteinase-3(MMP-3）,matrix metalloproteinase-13(MMP-13） and prostaglandin E2(PGE2） levels by enzyme linked immunosorbent assay(ELISA）. The clinical efficacy and adverse drug reactions in two groups were compared. Results After treatment,the levels of Lequesne indexes in treatment group and control group were 5. 78 ± 3. 04 and 8. 24 ± 3. 62,Lysholm scores were 85. 82 ± 10. 01 and72. 46 ± 13. 58,VAS scores were 2. 45 ± 1. 08 and 3. 86 ± 1. 17,serum MMP-3 levels were(114. 69 ± 13. 54） and(130. 52 ± 16. 48） ng·L-1,serum MMP-13 levels were(141. 06 ± 21. 55） and(179. 82 ± 24. 37） ng·L-1,serum PGE2 levels were(69. 82 ± 18. 67） and(91. 30 ± 20. 09） ng·L-1,joint fluid MMP-3 levels were(17. 89 ± 5. 12） and(23. 10 ± 5. 46） ng·L-1,joint fluid MMP-13 levels were(27. 35 ± 6. 52） and(38. 47 ± 6. 85） ng·L-1,joint fluid PGE2 levels were(82. 16 ± 22. 64） and(118. 02 ± 23. 41） ng·L-1,all with significant difference(all P〈0. 05）. The improvement rates of control group and treatment group were 73. 33%(33 cases/45 cases）,91. 11%(41 cases/45 case）,with significant difference(P〈0. 05）. No adverse drug reactions occurred during the treatment. Conclusion The clinical effect of meloxicam combined with glucosamine sulfate in the treatment of knee osteoarthritis is exact,the treatment i

关 键 词：美洛昔康 硫酸氨基葡萄糖 骨关节炎 

分 类 号：R97[医药卫生—药品]